WO2025094065 - AMINO-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
National phase entry is expected:
Publication Number
WO/2025/094065
Publication Date
08.05.2025
International Application No.
PCT/IB2024/060683
International Filing Date
30.10.2024
Title **
[English]
AMINO-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
[French]
COMPOSÉS DE PYRIDAZINE À SUBSTITUTION AMINO UTILISÉS EN TANT QU'AGENTS DE DÉGRADATION DE SMARCA2 ET/OU DE SMARCA4
Applicants **
AURIGENE ONCOLOGY LIMITED
39-40 (P), KIADB Industrial Area, Electronics City Phase II
Bangalore 560100, IN
Inventors
ABBINENI, Chandrasekhar
Plot#387, IKIGAI Journalists' colony phase 3, Gopanpally
Hyderabad 500032, IN
SAMAJDAR, Susanta
R801, HMTambourine, JP Nagar 6th Phase,
Bangalore 560078, IN
KUILA, Bilash
Vill+PO+PS-Shyampur, Dist-Howrah, West Bengal
Howrah 711314, IN
Priority Data
202341074562
01.11.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2748 | |
| EPO | Filing, Examination | 16995 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 13685 |
Total: 34596 USD
Abstract[English]
The present disclosure provides amino-substituted pyridazine compounds of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or delaying progression of disease or disorder dependent upon SMARCA2 and/or SMARCA4 in a subject. The present disclosure also provides pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.[French]
La présente divulgation concerne des composés de pyridazine à substitution amino de formule (I), qui sont thérapeutiquement utiles en tant qu'agents de dégradation de SMARCA2 et/ou de SMARCA4. Ces composés sont utiles dans le traitement et/ou le retardement de la progression d'une maladie ou d'un trouble dépendant de SMARCA2 et/ou de SMARCA4 chez un sujet. La présente divulgation concerne également des compositions pharmaceutiques comprenant au moins l'un des composés de formule (I) ou un sel pharmaceutiquement acceptable ou un stéréoisomère ou un tautomère de celui-ci.